← Back
$TCRX All transactions

TScan Therapeutics, Inc.

▲ BUY
9 / 10

Conviction

$ Value

$1.7M

Shares

1,388,794

Price

$1

Filed

May 21

Why this score? (9/10)
  • Open market buy (+3)
  • Trade value >= $1.0M (+2)
  • % of holdings >= 20% (+2)
  • 10%+ owner (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

Lynx1 Capital Management LP

Title

CIK

0001910456

Roles

10% Owner

Transaction Details

Transaction Date

2025-05-19

Code

P

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

6,746,141

Footnotes

The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Filing Info

Accession No.

0000902664-25-002511

Form Type

4

Issuer CIK

0001783328

Lynx1 Capital Management LP's History

Date Ticker Type Value
2026-03-31 KRRO $6K
2025-10-28 CGEM $1.4M
2025-10-21 NEUP $3.3M
2025-10-17 CGEM $253K
2025-10-16 CGEM $1.3M
2025-10-15 CGEM $409K
2025-10-14 CGEM $114K
2025-10-10 CGEM $2.0M
2025-10-09 CGEM $4.2M
2025-10-08 CGEM $3.6M

Other Insiders at TCRX (90d)

No other insider activity at this issuer in the last 90 days.